Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Sep 05, 2018 5:03pm

146 Views

Post# 28568290

RE:Citagenix

Citagenix was acquired by Antibe about 2 or 3 years ago for around 10 Million i think.
Antibe now owns them, they are a susbsiduary of Antibe.
check the financial,
maybe the investor presentation is a good place to start:
https://www.antibethera.com/wordpress/pdf/presentations/Antibe%20Investor%20Presentation%20-%20July%202018.pdf

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading